| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1399-3038.1997.TB00138.X |
| P698 | PubMed publication ID | 9260215 |
| P2093 | author name string | T Hirsch | |
| W Leupold | |||
| M Sähn | |||
| P433 | issue | 1 | |
| P921 | main subject | placebo | Q269829 |
| immunotherapy | Q1427096 | ||
| Dermatophagoides pteronyssinus | Q4573411 | ||
| P304 | page(s) | 21-27 | |
| P577 | publication date | 1997-02-01 | |
| P1433 | published in | Pediatric Allergy & Immunology | Q14064731 |
| P1476 | title | Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children | |
| P478 | volume | 8 |
| Q36864947 | Allergen immunotherapy for allergic respiratory diseases |
| Q39038000 | Allergen immunotherapy in asthma; what is new? |
| Q39649421 | Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis |
| Q38104712 | Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review |
| Q49485552 | Applicability of evidence from previous systematic reviews on immunotherapy in current practice of childhood asthma treatment: a GRADE (Grading of Recommendations Assessment, Development and Evaluation) systematic review |
| Q38481969 | Clinical and Immunologic Effects of Sublingual Immunotherapy on Patients with Allergic Rhinitis to House-Dust Mites: 1-Year follow-up Results |
| Q72996277 | Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study |
| Q64447287 | Cochrane Review: Sublingual immunotherapy for treating allergic conjunctivitis |
| Q38845293 | Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study |
| Q35849524 | Efficacy and safety of sublingual immunotherapy |
| Q36308157 | Efficacy of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis: A Meta-Analysis of Randomized Controlled Trials |
| Q34561153 | Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials |
| Q51728271 | Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study. |
| Q37102423 | European allergen extract units and potency: review of available information. |
| Q43795634 | Food anaphylaxis in schools: evaluation of the management plan and the efficiency of the emergency kit. |
| Q35777126 | Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Asso |
| Q73714861 | House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study |
| Q81203088 | Immunotherapy |
| Q43776098 | Immunotherapy with an oral Alternaria extract in childhood asthma. Clinical safety and efficacy and effects on in vivo and in vitro parameters |
| Q75387597 | Is oral immunotherapy too good to be true? |
| Q40616842 | Is sublingual immunotherapy the final answer? Implications for the allergist |
| Q37304734 | New types of immunotherapy in children. |
| Q73120444 | Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients |
| Q35718674 | Progress in the management of childhood asthma |
| Q55527154 | Sub-lingual immunotherapy: world allergy organization position paper 2009. |
| Q37304729 | Subcutaneous and sublingual immunotherapy in children: complete update on controversies, dosing, and efficacy |
| Q36194445 | Sublingual Immunotherapy for Asthmatic Children Sensitized to House Dust Mite: A Meta-Analysis |
| Q58700135 | Sublingual allergen immunotherapy for respiratory allergy: a systematic review |
| Q41383161 | Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children. |
| Q24235551 | Sublingual immunotherapy for allergic rhinitis |
| Q24248657 | Sublingual immunotherapy for allergic rhinitis |
| Q24187736 | Sublingual immunotherapy for asthma |
| Q24235657 | Sublingual immunotherapy for treating allergic conjunctivitis |
| Q33204109 | Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature |
| Q47852864 | Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period |
| Q36994648 | Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations |
| Q42662221 | Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule |
| Q53729251 | Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. |
| Q73733370 | [Sublingual immunotherapy in children. Immunotherapy Committee of the Spanish Society for Clinical Immunology and Pediatric Allergology] |
Search more.